Global Information Inc. would like to present a new market research report, "The Worldwide Market for In Vitro Diagnostic Tests, 8th Edition" by Kalorama Information.
A large number of acquisitions and partnerships occurred in the in vitro diagnostics industry over the past two years, a sign of the frenetic pace of the industry, according to Kalorama Information. The healthcare market research publisher said there were at least 105 acquisitions and distribution agreements in the IVD market just in the past two years, the majority of which were acquisitions.
"The future of the industry lies in the development of more sensitive, faster, user-friendly, IT capable devices for a host of new protein and molecular markers," said Shara Rosen, R.T. MBA, the author and lead diagnostic analyst for Kalorama Information. "No company, big or small, owns all of the technology needed to develop these new tests and systems."
The report cites some examples of acquisitions that have occurred since 2010:
- Danaher Corporation purchased IVD leader Beckman Coulter
- Agilent Technologies purchased FISH/IHC leader Dako
- Roche entered a development agreement with Dexcom for its SEVEN PLUS continuous glucose monitor system and purchased the RALS IT connectivity system from Medical Automation Systems
- Abbott acquired STARLIMS lab IT system and Biofortuna s freeze-dried SSPGo HLA typing kits
- Terumo Corporation of Japan merged with CaridianBCT a blood unit processing company
- Perkin Elmer acquired Caliper Life Sciences
- Gen-Probe invested $50 million in Pacific Biosciences, known for its SMRT sequencing platform
- Quest purchased Celera, a maker of genetic tests
"These announcements are just a small portion of what is really happening," said Rosen. "There are many more deals that have not been announced."
According to the report, a number of totally disparate phenomena have come together for IVD at the same time. Human genome research is finding links between a persons genome and several lifestyle situations such as nutrition, dieting, skin conditions and other essentially non-medical conditions. This has attracted consumer product companies such as Proctor & Gamble and Nestle to develop products and services based on IVD technologies. Decreases in life science grants have encouraged companies active in this space to migrate their technologies for clinical applications. The result is the entry of companies such as Caliper Life Sciences, Illumina, Affymetrix and Life Technologies to the diagnostics market with products and test services. Miniaturization of traditional immunoassay and molecular test technologies has finally matured to the point where it may be ready for scale-up and then commercialization into products. This has attracted electronics companies such as Sony, Samsung, Dell Computers and Intel to invest in clinical diagnostics ventures. Kalorama Information believes these trends are combining to push growth in the 50+ billion-dollar IVD industry.